FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2784549882> ?p ?o ?g. }

• W2784549882 abstract "Situation Patient A and B are 9 and 4 year old siblings with developmental delay and in particular; speech delay, seizures and behavioural difficulties. They were found to have GAMT deficiency due to a heterozygous pathogenic GAMT splicing mutation c.327G>A and pathogenic GAMT nonsense mutation c.522G>A (Trp174Ter). Patient A and B were referred to the regional metabolic team for further input. Management of this rare disorder involves combination treatment with specialist medications and a protein restricted diet. 1,2 Background GAMT deficiency is an inherited disorder of creatine synthesis. 1,2 Approximately 110 patients have been diagnosed world wide. 1 Main clinical features are intellectual disability with speech and language delay, behavioural problems and epilepsy. 1,2 Creatine is an important energy source formuscle and brain. The enzyme arginine: amidinotransferase (AGAT) synthesises guanidinoacetate (GAA) using arginine and glycineas substrates. 1,2 The enzyme GAMT in the liver then catalyses the last step of creatine synthesis converting GAA into creatine. 1,2 Creatine is transported via the bloodstream to other organs where it is utilised. 1 In GAMT deficiency there is a deficiency of creatine and an excess of GAA causing neurotoxicity. The sibling’s history and presentation were consistent with GAMT deficiency and plasma GAA levels done before starting ornithine were very elevated confirming the genetic finding. Treatment Creatine supplementation restores deficient levels. L-Ornithine competitively inhibits the enzyme AGAT reducing GAA synthesis. An arginine restricted diet and sodium benzoate deprives the pathway of arginine and glycine respectively reducing GAA synthesis. 1,2 Outcome 6 months after starting treatment with creatine (400 mg/kg/day) and l-ornithine (400 mg/kg/day), a significant clinical improvement has been observed. Patient A has had improvement in memory recall, speech and sleeping, and her seizures have reduced from daily to occasionally. Her plasma GAA levels have decreased from 13.3 to 6.5 micromoles/L (0.8–3.1 micromole/L). A bigger improvement has been seen for patient B, probably explained by an earlier age of intervention. Seizures have stopped, with normalisation of his electroencephalogram. His behaviour, attention span and speech have improved, with an ability to form sentences and a widening vocabulary. He is able to walk up the stairs rather than crawl or bottom-shuffle. His plasma GAA has decreased from 14.7 to 8.0 micromoles/L. Doses of l-ornithine and creatine have been increased further to 600 mg/kg/day. Both have had brain magnetic resonance spectroscopy on treatment showing there is no creatine deficiency. Lessons learnt Management of GAMT deficiency requires multidisciplinary input with pharmacy playing an important role advising on treatment, dosing and formulation, and sourcing ornithine and creatine of pharmaceutical grade that is palatable for children. As with very rare disorders, recommendations for treatment are based on case reports and expert opinion. However, there is an emerging pattern that combined treatment started early has the best outcome with normal development sometimes being reported. The siblings struggled with the diet so pharmaceutical intervention is the mainstay of management. If GAA levels fail to fall and/or remain low then sodium benzoate may be introduced. 1 References Saudubray JM, Baumgartner MR, Walter J. Inborn metabolic diseases: Diagnosis and treatment 2016;6th ed. Berlin: Springer. Stockler-Ipsiroglu S, Van Karnebeek C, Longo N, et al. Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Molecular Genetics and Metabolism2014;111:16–25." @default.
• W2784549882 created "2018-02-02" @default.
• W2784549882 creator A5021044254 @default.
• W2784549882 creator A5041885303 @default.
• W2784549882 creator A5044121233 @default.
• W2784549882 creator A5059287959 @default.
• W2784549882 date "2018-01-19" @default.
• W2784549882 modified "2023-09-27" @default.
• W2784549882 title "P19 Clinical pearl: pharmaceutical management of siblings with guanidinoacetate methyltransferase (gamt) deficiency" @default.
• W2784549882 doi "https://doi.org/10.1136/archdischild-2017-314584.30" @default.
• W2784549882 hasPublicationYear "2018" @default.
• W2784549882 type Work @default.
• W2784549882 sameAs 2784549882 @default.
• W2784549882 citedByCount "0" @default.
• W2784549882 crossrefType "journal-article" @default.
• W2784549882 hasAuthorship W2784549882A5021044254 @default.
• W2784549882 hasAuthorship W2784549882A5041885303 @default.
• W2784549882 hasAuthorship W2784549882A5044121233 @default.
• W2784549882 hasAuthorship W2784549882A5059287959 @default.
• W2784549882 hasConcept C104317684 @default.
• W2784549882 hasConcept C118552586 @default.
• W2784549882 hasConcept C126322002 @default.
• W2784549882 hasConcept C134018914 @default.
• W2784549882 hasConcept C2776796294 @default.
• W2784549882 hasConcept C2777172819 @default.
• W2784549882 hasConcept C2777468819 @default.
• W2784549882 hasConcept C2778186239 @default.
• W2784549882 hasConcept C2779896295 @default.
• W2784549882 hasConcept C501734568 @default.
• W2784549882 hasConcept C515207424 @default.
• W2784549882 hasConcept C55493867 @default.
• W2784549882 hasConcept C71924100 @default.
• W2784549882 hasConcept C75563809 @default.
• W2784549882 hasConcept C86803240 @default.
• W2784549882 hasConcept C96777560 @default.
• W2784549882 hasConceptScore W2784549882C104317684 @default.
• W2784549882 hasConceptScore W2784549882C118552586 @default.
• W2784549882 hasConceptScore W2784549882C126322002 @default.
• W2784549882 hasConceptScore W2784549882C134018914 @default.
• W2784549882 hasConceptScore W2784549882C2776796294 @default.
• W2784549882 hasConceptScore W2784549882C2777172819 @default.
• W2784549882 hasConceptScore W2784549882C2777468819 @default.
• W2784549882 hasConceptScore W2784549882C2778186239 @default.
• W2784549882 hasConceptScore W2784549882C2779896295 @default.
• W2784549882 hasConceptScore W2784549882C501734568 @default.
• W2784549882 hasConceptScore W2784549882C515207424 @default.
• W2784549882 hasConceptScore W2784549882C55493867 @default.
• W2784549882 hasConceptScore W2784549882C71924100 @default.
• W2784549882 hasConceptScore W2784549882C75563809 @default.
• W2784549882 hasConceptScore W2784549882C86803240 @default.
• W2784549882 hasConceptScore W2784549882C96777560 @default.
• W2784549882 hasLocation W27845498821 @default.
• W2784549882 hasOpenAccess W2784549882 @default.
• W2784549882 hasPrimaryLocation W27845498821 @default.
• W2784549882 hasRelatedWork W1580554837 @default.
• W2784549882 hasRelatedWork W185449676 @default.
• W2784549882 hasRelatedWork W1957050290 @default.
• W2784549882 hasRelatedWork W1971060324 @default.
• W2784549882 hasRelatedWork W1973856239 @default.
• W2784549882 hasRelatedWork W201525222 @default.
• W2784549882 hasRelatedWork W2027428988 @default.
• W2784549882 hasRelatedWork W2035456795 @default.
• W2784549882 hasRelatedWork W2039255263 @default.
• W2784549882 hasRelatedWork W2067360430 @default.
• W2784549882 hasRelatedWork W2086563255 @default.
• W2784549882 hasRelatedWork W2099101508 @default.
• W2784549882 hasRelatedWork W2167247297 @default.
• W2784549882 hasRelatedWork W2415556257 @default.
• W2784549882 hasRelatedWork W2606976889 @default.
• W2784549882 hasRelatedWork W2791088236 @default.
• W2784549882 hasRelatedWork W2940570219 @default.
• W2784549882 hasRelatedWork W2965406545 @default.
• W2784549882 hasRelatedWork W2976422566 @default.
• W2784549882 hasRelatedWork W2775161575 @default.
• W2784549882 isParatext "false" @default.
• W2784549882 isRetracted "false" @default.
• W2784549882 magId "2784549882" @default.
• W2784549882 workType "article" @default.